Format

Send to

Choose Destination
Curr Urol Rep. 2016 Jun;17(6):46. doi: 10.1007/s11934-016-0600-8.

Testosterone Replacement Therapy and BPH/LUTS. What is the Evidence?

Author information

1
Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA.
2
Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA. tkohler@siumed.edu.

Abstract

Contrary to the previous dogma that prostatic growth is directly proportional to testosterone levels, emerging research has suggested a lack of testosterone may be a risk factor for lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Within this review article, we have demonstrated the current understanding of the physiology of hypogonadism and its interplay with prostatic and lower urinary tract physiology. The current evidence suggests that not only does testosterone replacement therapy (TRT) not worsen LUTS, but that hypogonadism itself is an important risk factor for LUTS/BPH.

KEYWORDS:

Benign prostatic hyperplasia; Lower urinary tract symptoms; Testosterone replacement therapy

PMID:
27068735
DOI:
10.1007/s11934-016-0600-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center